In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Lloyd

Advertisement
Set Alert for Articles By Ian Lloyd

Latest From Ian Lloyd

Infographic – 2018 Pharma Pipeline Snapshot

Infographic examines the current status of biopharma pipelines by trial phase, company, and therapeutic areas.

Clinical Trials Research & Development

GSK regains pipeline top spot

GlaxoSmithKline (GSK) has regained the crown of for the most drugs in development by a pharma company after two years of being displaced by Pfizer, despite reporting a small drop in the number of its R&D products.

Japan

A year in pharma and biotech R&D: The druggable genome lives on

A decade ago, the publication of the human genome foreshadowed an explosion in new drug targets. Those predictions now seem to have been overly optimistic.

Cancer

A year in pharma and biotech R&D: Glimmers of hope in Phase III

At last, some signs that the pharma industry is addressing attrition in the late-stage pipeline – with the biggest annual rise in Phase III products on record.

A year in pharma and biotech R&D: Cancer resumes its march

The drop in pipeline cancer compounds in 2009 turned out to be a temporary blip.

Cancer Neurology

A year in pharma and biotech R&D: Lack of large M&As leads to little change

No surprises in the top 10, but the number of smaller companies involved in R&D, including a wealth of start-ups, continues on its unrelenting growth trajectory.

Cancer
See All
Advertisement
UsernamePublicRestriction

Register